Crista Galli Ventures

Crista Galli Ventures is a venture capital firm established in 2019, with offices in Copenhagen, Denmark, and London, United Kingdom. The firm focuses on investing in early-stage startups, particularly in the health technology, digital health, and deep technology sectors. Crista Galli Ventures provides patient capital to support companies at the pre-seed, seed, and Series A stages, typically investing up to £0.5 million at the seed level and up to £3 million at the Series A level. The firm prioritizes investments in pan-European companies, aiming to foster innovation and growth in the healthcare landscape.

Søren Fryland Møller

Partner

32 past transactions

Vitrue Health

Seed Round in 2024
Vitrue Health focuses on developing digital technology to address musculoskeletal issues through accurate measurement and analysis. Their flagship product, VIDA, is a comprehensive service aimed at reducing problems such as back and neck pain among desk workers by ensuring compliance with ergonomic standards for remote, office, and hybrid environments. Utilizing advanced AI, VIDA assesses workspace quality and empowers employees with knowledge to improve their environments, thereby enhancing their overall well-being. Additionally, Vitrue's EVVA technology employs depth sensors for clinical-grade assessments in orthopaedics and injury prevention, offering precise evaluations of functional movements throughout rehabilitation. By leveraging computer vision and biomechanics, Vitrue Health not only collects and analyzes health data but also provides actionable insights to both clinicians and patients, promoting early detection of issues and informed decision-making in treatment plans. Their mission is to transform musculoskeletal healthcare and significantly reduce pain for millions of individuals.

Jude

Seed Round in 2023
Jude is a healthcare company focused on addressing bladder health issues and raising awareness about incontinence. The organization offers a range of services that include expert advice from medical professionals through social media, virtual seminars, and private chat options. Additionally, Jude provides health products designed to assist individuals in managing their bladder health effectively. By combining educational resources with accessible support, Jude aims to empower individuals to understand their medical conditions and pursue solutions for a leak-free life.

Collective Minds Radiology

Venture Round in 2023
Collective Minds Radiology is a cloud-based healthcare company that provides a digital platform for radiologists to collaborate on diagnosing imaging findings. The platform facilitates the sharing of cases among experts and hospitals, allowing for clinical audits that help monitor quality and improve diagnostic accuracy. In addition to fostering collaboration, the company offers clinical consultation, research, and educational services, building a network that combines human expertise with artificial intelligence. This innovative approach aims to enhance the capabilities of healthcare professionals and create a comprehensive reference library for improved analysis.

Gleamer

Series B in 2023
Gleamer develops artificial intelligence solutions tailored for radiology, focusing on enhancing diagnostic accuracy and efficiency in medical imaging. The company's AI Companions integrate seamlessly into the existing workflow of radiologists, providing automated second readings that assist in detecting and highlighting bone abnormalities on X-ray images. This technology enables the early identification of lesions and prioritization of patient care, helping to ensure that diagnoses are made promptly and accurately. Currently, Gleamer's solutions are utilized in over 300 institutions across 13 countries, reflecting the widespread adoption of its advanced diagnostic tools in the healthcare sector.

Pear Bio

Series A in 2023
Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

52 North

Seed Round in 2023
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

Subtle Medical

Series B in 2022
Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Surgery Hero

Seed Round in 2022
Surgery Hero is a pioneering digital prehabilitation clinic focused on helping individuals prepare for and recover from surgery in the comfort of their homes. By optimizing both physical and mental health prior to surgical procedures, the platform aims to reduce the risk of complications and enhance recovery. Through a combination of expert health coaches and digital guidance, Surgery Hero provides members with the necessary tools and lifestyle habits that have been shown to improve surgical outcomes. This innovative approach allows patients to effectively prepare for surgery and ensures a safer recovery process.

CardiaTec Biosciences

Pre Seed Round in 2022
CardiaTec is a digital biotechnology company focused on revolutionizing cardiovascular drug discovery through the integration of artificial intelligence and specialized expertise. The company aims to transform the understanding of cardiovascular disease by developing AI-driven platforms for target identification and novel drug discovery. This approach seeks to provide effective therapeutics for cardiovascular diseases, addressing significant gaps in diagnostics, patient stratification, and treatment options for conditions such as coronary artery disease. By leveraging advanced technology and scientific knowledge, CardiaTec is dedicated to improving healthcare outcomes related to cardiovascular health.

Adni

Seed Round in 2022
Adni is transforming the career management of healthcare workers through an AI-powered super app that consolidates essential services into a single platform. The application facilitates connections between healthcare professionals and high-paying job opportunities while also offering resources for purchasing gear, updating credentials, and networking with peers. In addition, it provides daily educational content to enhance professional development. For healthcare employers, Adni serves as a comprehensive solution for both recruiting and retaining talent. Unlike conventional job boards and recruiting software, Adni focuses on fostering engagement and satisfaction among current staff through its unique platform, which includes features such as a white-labeled gamified intranet. This dual approach benefits both healthcare workers and employers by streamlining processes and enhancing overall engagement within the industry.

Anja

Seed Round in 2022
Anja Health is a personalized cord blood banking company that specializes in the preservation of umbilical cord and placenta stem cells. The company provides a collection kit to expectant parents, allowing for up to two minutes of delayed cord clamping after birth. Once the baby is born, parents can notify Anja Health, and a medical courier will promptly pick up the kit and deliver it to a lab within 72 hours. Anja Health aims to make stem cell preservation accessible and affordable, offering services that include the cryopreservation of umbilical cord blood for potential stem cell treatments. Additionally, the company collaborates with various microfinance partners and institutions to enhance service delivery to its customers.

52 North

Seed Round in 2022
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.

Apryl

Seed Round in 2022
Apryl is a fertility benefits platform designed to address inequality in the workplace by providing comprehensive support for employees seeking family planning options. The platform assists employers in attracting and retaining top talent by offering a range of fertility and family planning benefits, including consultations, access to clinics, and treatments such as egg freezing, in vitro fertilization (IVF), and adoption services. By enabling employees to receive confidential support from their employers, Apryl fosters a more inclusive work environment that prioritizes the diverse needs of its workforce.

Noula

Pre Seed Round in 2022
Noula is a precision hormonal health company focused on bridging the maternal health gap by providing personalized reproductive health insights to birthing parents. The company offers at-home test kits that assess hormone biomarkers, genetics, nutrition, and lifestyle factors, allowing for the development of tailored wellness plans. Noula's approach emphasizes a whole-person perspective, integrating unique health data with one-on-one coaching from empathetic clinicians. This virtual support empowers patients to make informed decisions about their health, facilitating a healthy pregnancy, birth, and post-birth experience.

LEIA Health

Angel Round in 2021
LEIA is a developer of a postpartum support application designed to assist new parents in their transition into parenthood. The app offers personalized insights into both mental and physical health, delivering medically validated information and practical tools to enhance overall well-being. It includes screening models for postpartum depression and pelvic floor complications, allowing women to identify potential risks early and connect with appropriate healthcare providers. This comprehensive approach aims to simplify the challenges of parenthood and promote healthier outcomes for new families.

Charco Neurotech

Seed Round in 2021
Charco Neurotech is a medical technology company focused on developing non-invasive wearable devices aimed at improving the quality of life for individuals with Parkinson's disease. The company's primary product is designed to modulate sensory dysfunction, which assists users in enhancing their movement speed. By providing a solution that allows people with Parkinson's to maintain a more normal lifestyle, Charco Neurotech addresses significant challenges faced by this population, ultimately contributing to better overall health and well-being.

Sanome

Pre Seed Round in 2021
Sanome is focused on addressing the growing demand for healthcare services by enhancing early detection and prevention strategies. The company has developed a predictive analytics tool that aids clinicians in identifying patient health changes earlier, thereby improving decision-making in clinical settings. By integrating healthcare data with advanced artificial intelligence and biophysical biomarkers, including at-home composite tests, Sanome's platform provides actionable clinical insights. This approach enables healthcare providers to detect potential health issues before they escalate, ultimately leading to better patient outcomes and increased operational efficiency. The company's long-term vision includes creating a human digital twin that continuously monitors individual health, informing clinicians about significant changes through its Clinical Co-pilot.

Pear Bio

Seed Round in 2021
Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Parallel Health

Pre Seed Round in 2021
Powered by genomics, skin microbiome science, and machine learning, Parallel is an end-to-end next-generation skin health company providing derm telehealth, cutting-edge skin microbiome diagnostics, precision microbiome skincare, and personalized Rx

Contextflow

Series A in 2021
contextflow GmbH is a company based in Vienna, Austria, specializing in machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, it has developed a 3D image-based search engine that enables radiologists to quickly identify regions of interest in medical images, particularly in lung CT scans. This technology allows for the rapid retrieval of similar cases and relevant clinical information, enhancing decision-making processes in diagnostics. contextflow's software is designed to integrate seamlessly with existing radiology workflows, thereby improving efficiency and patient care. The company has established strategic partnerships with various organizations, including radiology centers and health associations, and is currently conducting trials of its software with multiple partners. Recognized for its innovation, contextflow has received several awards and was selected to participate in an accelerator program aimed at advancing health technology.

Pear Bio

Seed Round in 2020
Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Radiobotics

Seed Round in 2020
Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.

Subtle Medical

Series A in 2020
Subtle Medical, Inc. is a healthcare technology company based in Menlo Park, California, that specializes in developing AI-powered medical imaging software for clinical imaging centers and hospitals. Founded in 2017, the company offers products such as SubtleMR and SubtlePET, both of which are FDA cleared and CE marked. These technologies enhance image quality in magnetic resonance imaging (MRI) and positron emission tomography (PET) exams by reducing noise and increasing sharpness, ultimately improving workflow efficiency while ensuring patient safety. Subtle Medical also features SubtleGAD, a technology recognized by the Radiological Society of North America, which aims to make imaging exams safer. The company employs a vendor-agnostic AI infrastructure that integrates seamlessly with existing scanners, allowing imaging providers to serve more patients effectively by enhancing image acquisition without disrupting their current workflow. Through its innovations, Subtle Medical seeks to improve the quality, value, and accessibility of medical imaging while significantly lowering costs and radiation exposure.

Radiobotics

Pre Seed Round in 2020
Radiobotics focuses on developing advanced machine learning algorithms that assist healthcare professionals in the analysis of medical images, particularly x-rays of bones and joints. By automating the reading of these images, the company's technology streamlines routine tasks and enhances access to radiology reports. This innovation aims to improve diagnostic quality, supporting doctors in making informed medical decisions more efficiently.

Gleamer

Series A in 2020
Gleamer develops artificial intelligence solutions tailored for radiology, focusing on enhancing diagnostic accuracy and efficiency in medical imaging. The company's AI Companions integrate seamlessly into the existing workflow of radiologists, providing automated second readings that assist in detecting and highlighting bone abnormalities on X-ray images. This technology enables the early identification of lesions and prioritization of patient care, helping to ensure that diagnoses are made promptly and accurately. Currently, Gleamer's solutions are utilized in over 300 institutions across 13 countries, reflecting the widespread adoption of its advanced diagnostic tools in the healthcare sector.

Pear Bio

Pre Seed Round in 2020
Pear Bio is a biotechnology company based in Boston and London that focuses on developing precision medicine therapeutics for challenging cancer cases. By analyzing tumor biopsies and blood samples from patients, the company utilizes multi-omics approaches to identify new therapeutic targets. Their proprietary immune-microtumor system allows them to test the effectiveness of drug candidates directly on patient tumor samples. Pear Bio's innovative technology includes a specialized hydrogel that cultivates tumors outside the human body, effectively simulating drug resistance and streamlining the treatment selection process. This enables the identification of the most effective therapies for individual patients, thereby reducing the reliance on trial-and-error methods in cancer treatment.

Quibim

Seed Round in 2020
Quibim, headquartered in Valencia, Spain, is a leader in whole-body medical imaging analysis, providing innovative AI-based image processing technologies. Its products, utilized by pharmaceutical companies and research teams globally, focus on extracting quantitative information from radiological images. Quibim Precision®, the company's whole-body imaging ecosystem, supports a variety of applications, from disease detection to monitoring the effectiveness of new treatments. By employing an AI-first approach, Quibim enables partners to accurately identify pathologies across different body parts and imaging modalities, ultimately enhancing the diagnosis of high-incidence illnesses and assessing treatment outcomes. This commitment to leveraging advanced imaging biomarkers contributes significantly to improving human health.

Ampersand Health

Seed Round in 2020
Ampersand Health is focused on developing digital therapeutics for individuals with long-term inflammatory conditions. Based in London and incorporated in 2014, the company offers a comprehensive digital platform that includes the Ampersand Healthsuite, a management tool designed for patients, and Healthsuite for Clinicians, which supports clinician-led, patient-centered self-management. The platform utilizes behavioral science to deliver personalized therapy, featuring expert-led courses, self-management tracking, and clinical messaging. Ampersand Health aims to enhance patients' mental health and quality of life while also providing significant cost savings for healthcare providers by reducing overall healthcare utilization.

Vitrue Health

Pre Seed Round in 2020
Vitrue Health focuses on developing digital technology to address musculoskeletal issues through accurate measurement and analysis. Their flagship product, VIDA, is a comprehensive service aimed at reducing problems such as back and neck pain among desk workers by ensuring compliance with ergonomic standards for remote, office, and hybrid environments. Utilizing advanced AI, VIDA assesses workspace quality and empowers employees with knowledge to improve their environments, thereby enhancing their overall well-being. Additionally, Vitrue's EVVA technology employs depth sensors for clinical-grade assessments in orthopaedics and injury prevention, offering precise evaluations of functional movements throughout rehabilitation. By leveraging computer vision and biomechanics, Vitrue Health not only collects and analyzes health data but also provides actionable insights to both clinicians and patients, promoting early detection of issues and informed decision-making in treatment plans. Their mission is to transform musculoskeletal healthcare and significantly reduce pain for millions of individuals.

Cerebriu

Seed Round in 2020
Cerebriu is a health tech company focused on advancing medical imaging through machine learning technologies. It specializes in creating a deep-learning-based AI platform that enhances workflow efficiency and quality in radiology. This innovative platform offers fully automated image quantification and biomarker indication, providing healthcare professionals with real-time decision support during examinations. By improving the accuracy and speed of medical imaging analysis, Cerebriu aims to contribute significantly to global healthcare solutions.

Contextflow

Venture Round in 2019
contextflow GmbH is a company based in Vienna, Austria, specializing in machine learning and artificial intelligence solutions for radiology image search and analysis. Founded in 2016, it has developed a 3D image-based search engine that enables radiologists to quickly identify regions of interest in medical images, particularly in lung CT scans. This technology allows for the rapid retrieval of similar cases and relevant clinical information, enhancing decision-making processes in diagnostics. contextflow's software is designed to integrate seamlessly with existing radiology workflows, thereby improving efficiency and patient care. The company has established strategic partnerships with various organizations, including radiology centers and health associations, and is currently conducting trials of its software with multiple partners. Recognized for its innovation, contextflow has received several awards and was selected to participate in an accelerator program aimed at advancing health technology.

Arthronica

Pre Seed Round in 2019
Arthronica Ltd is a London-based company that specializes in developing an artificial intelligence platform for patient monitoring and rehabilitation, particularly focused on chronic rheumatic conditions such as arthritis. Established in 2018, the company utilizes advanced technologies, including skeletal tracking, visual strength assessments, image analysis, and video analysis, to create solutions that assist medical practitioners in monitoring and predicting disease activities. Arthronica's innovative system incorporates force-sensing vision and 3D CAD modeling to measure swelling, thereby providing critical insights into disease progression. The company is actively engaged in clinical trials in both the United Kingdom and the United States to further validate its technology and enhance patient care. Additionally, Arthronica has participated in the Entrepreneur First program, which supports individuals in building technology companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.